{"id":"https://genegraph.clinicalgenome.org/r/8a5d6cd4-8368-406d-abca-afc3090ee220v2.1","type":"EvidenceStrengthAssertion","dc:description":"The first report of ciliopathy-*CEP164* was in 2012 by Chaki M et al. (PMID: 22863007). Individuals with ciliopathy-*CEP164* present with a broad range of phenotypes, including various combinations of nephronophthisis, respiratory system impact, retinal degeneration, developmental delay, CNS malformations, polydactyly, bronchiectasis and obesity. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found no difference in molecular mechanism and inheritance pattern. The spectrum of reported phenotypes encompassed various signs and symptoms associated with defects of both the primary and motile cilium, in line with the known roles of *CEP164*. Therefore, the following disease entities have been lumped into one disease entity: nephronophthisis 15 (MONDO:0013917) and Senior-Loken syndrome (MONDO:0017842). \n\nSeven different variants (2 missense, 3 nonsense, 1 frameshift and 1 stop loss) that have been reported in 6 probands in 4 publications (PMIDs: 22863007, 34132027, 27708425, 36273371) are included in this curation. The mechanism of pathogenicity is reported to be loss-of-function. Genetic variants have been associated with reduced protein interactions, ciliary defects and DNA damage. \n\nThis gene-disease association is also supported by expression studies, multiple animal models (zebrafish and mouse) as well as in vitro functional assays (PMIDs: 31990917, 22863007, 23150559, 29244804, 31248650). Ablation of cep164 protein in foxj1-positive mice tissues resulted in loss of airway multicilia and hydrocephalus, indicating its essential roles in airway multiciliated cell differentiation. A similar effect was also detected in ependymal cells, seminiferous tubules, and oviducts of the knockout mice (PMID: 29244804). The Zebrafish cep164 knockout model could recapitulate various aspects of the ciliopathy-disease spectrum, exhibiting ventral body axis curvature, laterality defects, hydrocephalus, kidney cysts, and retinal dysplasia (PMID: 22863007). One nonsense variant (p.Gln525Ter/p.Gln525Ter) has been associated with a dominant negative effect on cell growth (PMID: 22863007). The proband had bronchiectasis along with nephronophthisis and retinal affection. Delvin LA et al investigated the motile ciliopathy affection in a compound heterozygous patient carrying the aforementioned variant and a stop gain in the penultimate exon (NM_014956.5 c.4228C > T p.(Gln1410Ter) (PMID:36273371). The male fertile patient had a predominantly respiratory phenotype (bronchiectasis, recurrent lower respiratory tract infection, recurrent ear infection and low nasal nitric oxide) and loss of *CEP164* in the centriolar region in his nasal brushing (NB) and ALI‐cultured cells. High‐speed video microscopy of the patient's NB epithelium detected uncoordinated cilia with reduced ciliary beat amplitude, and lack of mucociliary clearance.\n\nIn summary, *CEP164* is definitively associated with autosomal recessive ciliopathy-*CEP164*. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Kidney Cystic and Ciliopathy Disorders GCEP on 10/27/21 (SOP Version 8).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/8a5d6cd4-8368-406d-abca-afc3090ee220","GCISnapshot":"https://genegraph.clinicalgenome.org/r/961b81f6-7ad1-49e2-b675-c035b4d8d35d","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/961b81f6-7ad1-49e2-b675-c035b4d8d35d_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10066","date":"2025-10-14T19:36:53.569Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/961b81f6-7ad1-49e2-b675-c035b4d8d35d_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10066","date":"2021-10-27T16:00:00.000Z","role":"Approver"},{"agent":"https://genegraph.clinicalgenome.org/agent/10102","role":"SecondaryContributor"}],"curationReasons":["DiseaseNameUpdate"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/961b81f6-7ad1-49e2-b675-c035b4d8d35d_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5bc8457c-09e5-4ac1-9016-6cba14682f8d_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5bc8457c-09e5-4ac1-9016-6cba14682f8d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22863007","rdfs:label":"KKESH001-7","allele":{"id":"https://genegraph.clinicalgenome.org/r/aa093d1d-ef77-41f0-9666-b3ac94c373b6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014956.5(CEP164):c.4383A>G (p.Ter1461TrpextTer57)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA382746593"}},"detectionMethod":"Combination of homozygosity mapping with whole-exome resequencing ","firstTestingMethod":"Homozygosity mapping","phenotypes":["obo:HP_0000556","obo:HP_0000618"],"secondTestingMethod":"Exome sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/f61b52e0-fa0b-4aba-90c9-2050d22a5a8f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22863007","allele":{"id":"https://genegraph.clinicalgenome.org/r/aa093d1d-ef77-41f0-9666-b3ac94c373b6"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/f61b52e0-fa0b-4aba-90c9-2050d22a5a8f","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f61b52e0-fa0b-4aba-90c9-2050d22a5a8f_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/f61b52e0-fa0b-4aba-90c9-2050d22a5a8f_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In IMCD3 cells, number of centrosomes positive for CEP164 is reduced upon  over-expression of C-terminally GFP-tagged human CEP164 (CGFP-hCEP164-WT), which mimics the mutation p.X1460WextX57\n","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/2ab0a74d-a246-421b-b904-3beefcbfbc08_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2ab0a74d-a246-421b-b904-3beefcbfbc08","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22863007","rdfs:label":"NPH505","allele":{"id":"https://genegraph.clinicalgenome.org/r/874ed6e5-e74c-4dc7-865c-d1370d7c499e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014956.5(CEP164):c.1726C>T (p.Arg576Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA130153"}},"detectionMethod":"exon-PCR & Sanger sequencing of all CEP164 exons","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0002110","obo:HP_0000090","obo:HP_0010442","obo:HP_0001513","obo:HP_0001999","obo:HP_0000546","obo:HP_0001320","obo:HP_0002910"],"sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/5b6a2140-a7c8-44b2-a5e7-bf27b2dd9bfe_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22863007","allele":{"id":"https://genegraph.clinicalgenome.org/r/874ed6e5-e74c-4dc7-865c-d1370d7c499e"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/5b6a2140-a7c8-44b2-a5e7-bf27b2dd9bfe","type":"EvidenceLine","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5b6a2140-a7c8-44b2-a5e7-bf27b2dd9bfe_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":3.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/9e2d2bf4-e618-49fc-aee0-dab39993e2ad_proband_score_evidence_line","type":"EvidenceLine","direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9e2d2bf4-e618-49fc-aee0-dab39993e2ad","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34556108","rdfs:label":"Family E","allele":[{"id":"https://genegraph.clinicalgenome.org/r/c8af51a0-2637-415d-bdda-47e16137a814","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014956.5(CEP164):c.4228C>T (p.Gln1410Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA6295761"}},{"id":"https://genegraph.clinicalgenome.org/r/874ed6e5-e74c-4dc7-865c-d1370d7c499e"}],"detectionMethod":"Whole genome sequencing","firstTestingMethod":"Other","phenotypes":["obo:HP_0002090","obo:HP_0012735","obo:HP_0001513","obo:HP_0012384","obo:HP_0002110"],"sex":"UnknownEthnicity","variant":[{"id":"https://genegraph.clinicalgenome.org/r/d22bb517-a079-4bce-95e7-6152d1c6082a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34556108","allele":{"id":"https://genegraph.clinicalgenome.org/r/874ed6e5-e74c-4dc7-865c-d1370d7c499e"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/3003c2cc-ae05-40cb-a529-742bd7fc7f93_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34556108","allele":{"id":"https://genegraph.clinicalgenome.org/r/c8af51a0-2637-415d-bdda-47e16137a814"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/3003c2cc-ae05-40cb-a529-742bd7fc7f93","type":"EvidenceLine","dc:description":"penultimate exon, 230/282374 alleles in gnomAD with AF 0.0014 in Europeans\n","calculatedScore":1.5,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3003c2cc-ae05-40cb-a529-742bd7fc7f93_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/d22bb517-a079-4bce-95e7-6152d1c6082a","type":"EvidenceLine","calculatedScore":1.5,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d22bb517-a079-4bce-95e7-6152d1c6082a_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/bb791081-07b6-4777-bfd8-3a51c08561b1_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bb791081-07b6-4777-bfd8-3a51c08561b1","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22863007","rdfs:label":"F319-21","allele":{"id":"https://genegraph.clinicalgenome.org/r/258d7b19-2889-4d0b-ae79-bc6de74fdf2a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014956.5(CEP164):c.32A>C (p.Gln11Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA130149"}},"detectionMethod":"exon-PCR & Sanger sequencing of all CEP164 exons","ethnicity":{"id":"cg:UnknownEthnicity"},"firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0003774","obo:HP_0000090","obo:HP_0000546"],"sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/bef6b7db-a4a5-4606-b4b0-20e9453dbbe3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22863007","allele":{"id":"https://genegraph.clinicalgenome.org/r/258d7b19-2889-4d0b-ae79-bc6de74fdf2a"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/bef6b7db-a4a5-4606-b4b0-20e9453dbbe3","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bef6b7db-a4a5-4606-b4b0-20e9453dbbe3_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/bef6b7db-a4a5-4606-b4b0-20e9453dbbe3_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Yes in different paper (34499853): Q11P directly compromises the CEP164/TTBK2 complex interface leading to reduced interaction between CEP164 and TTBK2. This mutation did not interfere with CEP164 localization to the mother centriole but reduced cilia formation in hTERT RPE1 cells. \n","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/d32b43ce-5f28-408b-8a83-135767e6fbf8_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d32b43ce-5f28-408b-8a83-135767e6fbf8","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36273371","rdfs:label":"II:2","allele":[{"id":"https://genegraph.clinicalgenome.org/r/874ed6e5-e74c-4dc7-865c-d1370d7c499e"},{"id":"https://genegraph.clinicalgenome.org/r/c8af51a0-2637-415d-bdda-47e16137a814"}],"detectionMethod":"Whole genome sequencing ","firstTestingMethod":"Other","phenotypeFreeText":"Mild learning ability, lifelong cough, hearing aids","phenotypes":["obo:HP_0002099","obo:HP_0025502","obo:HP_0012384","obo:HP_0002783","obo:HP_0410018","obo:HP_0002110","obo:HP_0012262"],"sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/938f1614-a156-4b5c-88b6-1f6f2fd2dec7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36273371","allele":{"id":"https://genegraph.clinicalgenome.org/r/c8af51a0-2637-415d-bdda-47e16137a814"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/5fea0642-dad6-4260-acd9-d08f2e09df7e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36273371","allele":{"id":"https://genegraph.clinicalgenome.org/r/874ed6e5-e74c-4dc7-865c-d1370d7c499e"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/5fea0642-dad6-4260-acd9-d08f2e09df7e","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5fea0642-dad6-4260-acd9-d08f2e09df7e_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/5fea0642-dad6-4260-acd9-d08f2e09df7e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Immunofluorescence assay demonstrated loss of CEP164 in the centriolar region in his nasal brushing (NB) and ALI‐cultured cells. High‐speed video microscopy of the patient's NB epithelium detected uncoordinated cilia with reduced ciliary beat amplitude, and lack of mucociliary clearance.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/938f1614-a156-4b5c-88b6-1f6f2fd2dec7","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/938f1614-a156-4b5c-88b6-1f6f2fd2dec7_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/938f1614-a156-4b5c-88b6-1f6f2fd2dec7_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Immunofluorescence assay demonstrated loss of CEP164 in the centriolar region in his nasal brushing (NB) and ALI‐cultured cells. High‐speed video microscopy of the patient's NB epithelium detected uncoordinated cilia with reduced ciliary beat amplitude, and lack of mucociliary clearance.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/5e0d7450-62f9-4baa-83af-f9ddc9425d07_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5e0d7450-62f9-4baa-83af-f9ddc9425d07","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22863007","rdfs:label":"F59-21 ","allele":[{"id":"https://genegraph.clinicalgenome.org/r/f1c16ed3-2ac3-4693-a8a1-7f0822f637c4","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014956.5(CEP164):c.1573C>T (p.Gln525Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA130151"}},{"id":"https://genegraph.clinicalgenome.org/r/be54cc54-053e-4827-9432-973170eab176","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014956.5(CEP164):c.277C>T (p.Arg93Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA130150"}}],"detectionMethod":"exon-PCR & Sanger sequencing of all CEP164 exons","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0000090","obo:HP_0003774","obo:HP_0000546"],"sex":"UnknownEthnicity","variant":[{"id":"https://genegraph.clinicalgenome.org/r/ad39b572-5bdd-4601-bd12-b43bef88f6a6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22863007","allele":{"id":"https://genegraph.clinicalgenome.org/r/be54cc54-053e-4827-9432-973170eab176"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/4edbfd4f-f63b-46ba-9c87-e5d41a210b3b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22863007","allele":{"id":"https://genegraph.clinicalgenome.org/r/f1c16ed3-2ac3-4693-a8a1-7f0822f637c4"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/ad39b572-5bdd-4601-bd12-b43bef88f6a6","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ad39b572-5bdd-4601-bd12-b43bef88f6a6_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/ad39b572-5bdd-4601-bd12-b43bef88f6a6_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"p.R93W mutation strongly lowered the thermostability of the CEP164-NTD and reduced interaction between CEP164 and TTBK2. p.R93W did not interfere with CEP164 localization to the mother centriole but showed a significant reduction in ARL13b-positive cilia formation compared with the WT construct in hTERT RPE1 cells (34499853).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/4edbfd4f-f63b-46ba-9c87-e5d41a210b3b","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4edbfd4f-f63b-46ba-9c87-e5d41a210b3b_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/4edbfd4f-f63b-46ba-9c87-e5d41a210b3b_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"-Abrogation of centrosomal signal for NGFP-CEP164-Q525X (IMCD3 & hTERT-RPE)\n-NGFP-hCEP164-Q525X fails to rescue ciliary defect in siCep164 transfected IMCD3 cells\n-CEP164-Q525X expression had a dominant negative effect on IMCD3 cell growth and didn’t rescue siCep164-mediated growth defect\n-Full length CEP164 but not the mutant CEP164-Q525X interacts with Dvl3 in HEK293 cells\n","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.5},{"id":"https://genegraph.clinicalgenome.org/r/938e9c33-b3b6-4e56-bcaa-342dc1ffd82b_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/938e9c33-b3b6-4e56-bcaa-342dc1ffd82b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27708425","rdfs:label":"F05 V:2","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":20,"allele":{"id":"https://genegraph.clinicalgenome.org/r/be54cc54-053e-4827-9432-973170eab176"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001249","obo:HP_0000771","obo:HP_0001513","obo:HP_0000556","obo:HP_0002059","obo:HP_0010442","obo:HP_0000135"],"previousTesting":true,"previousTestingDescription":"Targeted exome sequencing of 21 previously reported ciliopathy genes associated with BBS ","secondTestingMethod":"Homozygosity mapping","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/07473699-3821-4f78-abb0-14bd83d41de7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27708425","allele":{"id":"https://genegraph.clinicalgenome.org/r/be54cc54-053e-4827-9432-973170eab176"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/07473699-3821-4f78-abb0-14bd83d41de7","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/07473699-3821-4f78-abb0-14bd83d41de7_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/07473699-3821-4f78-abb0-14bd83d41de7_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"p.R93W mutation strongly lowered the thermostability of the CEP164-NTD and reduced interaction between CEP164 and TTBK2. p.R93W did not interfere with CEP164 localization to the mother centriole but showed a significant reduction in ARL13b-positive cilia formation compared with the WT construct in hTERT RPE1 cells (34499853).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/510a4286-5824-4188-9b29-14bbea080af3_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/510a4286-5824-4188-9b29-14bbea080af3","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34132027","rdfs:label":"Patient 1","allele":[{"id":"https://genegraph.clinicalgenome.org/r/9c3616b2-8cae-4263-b6cf-14aaca1733c0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014956.5(CEP164):c.3055C>T (p.Gln1019Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA6295311"}},{"id":"https://genegraph.clinicalgenome.org/r/5ba99de0-4ac8-459d-9bcc-1d164fdd39ec","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014956.5(CEP164):c.2535_2536dup (p.Glu846GlyfsTer10)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA942662030"}}],"detectionMethod":"Trio exome sequencing\n","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0010442","obo:HP_0002444","obo:HP_0004322","obo:HP_0000126","obo:HP_0000316","obo:HP_0100779","obo:HP_0001159","obo:HP_0001252","obo:HP_0001249","obo:HP_0000191","obo:HP_0010297","obo:HP_0011802","obo:HP_0002119"],"previousTesting":true,"previousTestingDescription":"Patient 1 had a chromosomal microarray performed, which showed a 470 base pair duplication of unclear clinical significance at 5q35.2 (hg19:175,668,563–176,138,247) including the NOP16, FAF2, SIMC1, CLTB, and SNCB genes. Parental testing was declined. ","sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/2ca68209-b307-406a-984a-f9a0c6f421e8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34132027","allele":{"id":"https://genegraph.clinicalgenome.org/r/9c3616b2-8cae-4263-b6cf-14aaca1733c0"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/54b5d0c7-dd7f-4ff4-ab41-7585c7b0998c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34132027","allele":{"id":"https://genegraph.clinicalgenome.org/r/5ba99de0-4ac8-459d-9bcc-1d164fdd39ec"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/2ca68209-b307-406a-984a-f9a0c6f421e8","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2ca68209-b307-406a-984a-f9a0c6f421e8_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/54b5d0c7-dd7f-4ff4-ab41-7585c7b0998c","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/54b5d0c7-dd7f-4ff4-ab41-7585c7b0998c_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/646d1ae7-e552-4c90-a70e-331c430b37de_proband_score_evidence_line","type":"EvidenceLine","direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/646d1ae7-e552-4c90-a70e-331c430b37de","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28125082","rdfs:label":"77-90","allele":[{"id":"https://genegraph.clinicalgenome.org/r/be54cc54-053e-4827-9432-973170eab176"},{"id":"https://genegraph.clinicalgenome.org/r/6b632b2a-1891-4d64-b65e-a1329e0cad3d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000011.10:g.117351788A>T (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA382725314"}}],"detectionMethod":"Targeted 27-gene Molecular Inversion Probes panel followed by whole-exome sequencing ","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0010442","obo:HP_0000090","obo:HP_0001392","obo:HP_0000546"],"sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/d89a5301-f81b-49ae-af98-5240f05351fb_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28125082","allele":{"id":"https://genegraph.clinicalgenome.org/r/be54cc54-053e-4827-9432-973170eab176"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/febb9ea9-edf4-4824-9488-1279f16385c3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28125082","allele":{"id":"https://genegraph.clinicalgenome.org/r/6b632b2a-1891-4d64-b65e-a1329e0cad3d"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/febb9ea9-edf4-4824-9488-1279f16385c3","type":"EvidenceLine","dc:description":"phase (trans or cis) not known as parental genotypes not determined ","calculatedScore":1.5,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/febb9ea9-edf4-4824-9488-1279f16385c3_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/d89a5301-f81b-49ae-af98-5240f05351fb","type":"EvidenceLine","dc:description":"phase (trans or cis) not known as parental genotypes not determined ","calculatedScore":0.5,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d89a5301-f81b-49ae-af98-5240f05351fb_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/d89a5301-f81b-49ae-af98-5240f05351fb_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"p.R93W mutation strongly lowered the thermostability of the CEP164-NTD and reduced interaction between CEP164 and TTBK2. p.R93W did not interfere with CEP164 localization to the mother centriole but showed a significant reduction in ARL13b-positive cilia formation compared with the WT construct in hTERT RPE1 cells (34499853).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.0}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/961b81f6-7ad1-49e2-b675-c035b4d8d35d_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/961b81f6-7ad1-49e2-b675-c035b4d8d35d_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9d7a766f-1e76-4ff4-b7ca-6b9bbe02c5ee","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4fbf7b16-9a81-4091-bfaf-f48666cf79f5","type":"Finding","dc:description":"MRC-Wellcome Trust Human Developmental Biology Resource (HDBR) to perform immunohistochemistry studies on human embryonic and foetal tissues to determine the expression patterns of CEP164 during development","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31990917","rdfs:label":"Human embryonic and foetal expression","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/df2e7300-ce7b-48be-8328-e2d68e720cf1","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d19caacd-4842-49c8-ac7c-ce4e0f7dbe62","type":"Finding","dc:description":"Using electron microscopy, CEP164 has been shown to be localized to the distal appendages of mature centrioles ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17954613","rdfs:label":"electron microscopy","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/4060182e-1b27-47fe-8e8f-14ae157f4594","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8d3b1830-dc49-4be4-9be3-c7b2c42b289f","type":"Finding","dc:description":"NPHP3 has been implicated in AR ciliopathies (OMIM 267010, 604387, 208540) and DVL3 is involved in the signal transduction pathway mediated by multiple Wnt genes (genecards) a signalling pathway implicated in ciliopathies.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22863007","rdfs:label":"Co-immunoprecipitation","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/b28cf2c1-e9bd-4902-9d9e-3b890b43ef69","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9bc61389-4fe7-493c-b564-8229399240f4","type":"Finding","dc:description":"In addition to centrosomes and the transition zone at the base of the primary cilium, CEP290 also localizes to the nucleus. Slaats et al. demonstrate that reduction of cellular CEP290 in primary human and mouse kidney cells as well as in zebrafish embryos leads to enhanced DNA damage signaling and accumulation of DNA breaks ex vivo and in vivo (26301811). Functional analyses of NEK8 mutations in patient fibroblasts and mIMCD3 cells showed that these mutations differentially affect ciliogenesis, proliferation/apoptosis/DNA damage response, as well as epithelial morphogenesis (26967905).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22863007","rdfs:label":"Morpholino knockdown in zf and DDR","demonstrates":{"id":"cg:BiochemicalFunctionA"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/961b81f6-7ad1-49e2-b675-c035b4d8d35d_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6cb70afe-dafa-45ea-b262-30f1e0b653e0","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fb8488e7-dc5d-4901-9e3d-96737752e6e2","type":"FunctionalAlteration","dc:description":"Tandem affinity purification (TAP) with MS using INPP5E as bait in HEK293T cells identifies CEP164 as an interaction partner (protein-protein interaction evidence). Ablation of CEP164 (siRNA) almost completely blocked cilia formation in RPE1 cells and INPP5E was not associated with the centrosome in CEP164-depleted, unciliated cells. CEP164 appears to be required for ciliary targeting of INPP5E in addition to ciliogenesis.\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23150559","rdfs:label":"CEP164 knockdown in vitro"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/961b81f6-7ad1-49e2-b675-c035b4d8d35d_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0de3cf76-adb4-4add-96c0-72ac68794b56","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/90247706-10e9-41aa-a8e1-09f6c15ea2ae","type":"Finding","dc:description":"siCep164 transfected cells manifest lower cilia frequencies compared to control transfected IMCD3 cells. Induction of NGFP-hCEP164-WT in siCep164 transfected cells rescues this ciliary defect. Ciliary frequency is not rescued by NGFP-hCEP164-Q525X.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22863007","rdfs:label":"Ciliary defect rescue in vitro","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityCellCultureRescueCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/dd2147f6-f02d-40f9-81e9-9a5677c9efc9","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c607190c-991d-4be5-bb37-54f4ecf5fefd","type":"Finding","dc:description":"Cep164 cKO mice were born at Mendelian ratio. Necropsy of postnatal day (P) 21 mice revealed that the mutant mice had severely enlarged kidneys compared to control mice. Within the first postnatal week the cysts expanded in size, but remained largely restricted to the kidney medullary region. In contrast, by P14 both medullary and cortical areas were filled with radially oriented, cystic distensions of collecting ducts in Cep164 cKO kidneys. A precipitous decline in kidney function occurred by P21, underlying the subsequent rapid lethality in Cep164 cKO mice. Primary cilia were present at similar levels in the proximal tubules of control and Cep164 cKO kidneys at P7 and P14. In contrast, no cilia were observed in the collecting duct lining epithelium of the mutant kidneys at P7 or P14, demonstrating that Cep164 is required for renal ciliogenesis.\n\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31248650","rdfs:label":"Collecting duct-specific CEP164 KO mouse","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/08537a41-db9b-4ec7-8c5c-374b6f58296d","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d73beea1-bb80-4460-8719-7f5160fb03bb","type":"Finding","dc:description":"At E9.5 and E10.5, CEP164-KO embryos exhibited holoprosencephaly, cardiac looping defects, an edematous pericardial sac, and a truncated posterior trunk. These phenotypes are similar to those reported for mouse mutants for KIF3A and KIF3B, which are major components of the kinesin-II ciliary anterograde motor, providing evidence for the essential role of CEP164 in primary ciliogenesis and for mammalian embryogenesis.\n\nSpecific ablation of CEP164 in multiciliated cells (CEP164fl/fl with Cre under FOXJ1 promoter) from the the airways, brain ventricles, oviducts and testis showed: \n- approx. 20% that succumbed to death due to severe hydrocephalus around weaning and another approx. 20% that exhibited mild hydrocephalus, which resolved itself later\n- substantial ventricular enlargement \n- A clear reduction in the number of ependymal multicilia \n- A marked decrease in the number of airway multicilia \n- Impaired mucociliary clearance\nThis is consistent with the primary ciliary dyskinesia/bronchiectasis phenotypes seen in patients\n\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29244804","rdfs:label":"Global and tissue specific (multiciliated) CEP164 KO mouse","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/0edceb34-3b5d-486b-9678-f52b4da2acfa","type":"EvidenceLine","dc:description":"Only 1 morpholino shown. Not validated by additional approaches (eg. Crispr/Cas9) ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/89039b24-0958-4745-acaf-33f040bc27fa","type":"Finding","dc:description":"Zebrafish phenotype reflects defects in motile and primary cilium. Human phenotype range evokes defects in motile and primary cilium as well. Human patients show similar kidney and eye phenotypes as observed in zebrafish.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22863007","rdfs:label":"Morpholino knockdown in zf ","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":12011,"specifiedBy":"GeneValidityCriteria8","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/HPYklfgGVOc","type":"GeneValidityProposition","disease":"obo:MONDO_0700344","gene":"hgnc:29182","modeOfInheritance":"obo:HP_0000007"},"version":"2.1","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_961b81f6-7ad1-49e2-b675-c035b4d8d35d-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}